#USA #New York #Hoth Therapeutics #HT-001 #EGFR Inhibitor

Hoth Therapeutics Showcases HT-001 Success in Treating Dermatologic Side Effects

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on enhancing patient outcomes, recently announced positive findings regarding its groundbreaking treatment, HT-001. This topical neurokinin 1 receptor (NK1R) antagonist has shown potential effectiveness in managing Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs).

The release of these findings comes just before the 2025 Annual Meeting of the American Academy of Dermatology (AAD), scheduled for March 7-11, 2025. The data presented will emphasize HT-001’s potential as a noteworthy solution for dermatologic side effects triggered by EGFR inhibitors, often experienced by cancer patients.

In a recent case study of a 59-year-old female patient with metastatic breast cancer undergoing treatment with a combination of paclitaxel, trastuzumab, and pertuzumab, the challenges of EGFR inhibitors were showcased vividly. The patient manifested pruritic, burning red papules across her face, scalp, and upper back—a common adverse effect linked to EGFR inhibitors.

After just one week of utilizing HT-001 2% cream twice daily, the patient reported a complete resolution of symptoms and skin lesions without recurrence over the following three weeks. This remarkable outcome underscores the cream’s swift action in catering to acute dermatologic challenges faced by patients undergoing cancer treatment.

Robb Knie, CEO of Hoth Therapeutics, stated, "The findings highlight HT-001’s potential as a safe and effective treatment for patients suffering from EGFR inhibitor-associated skin toxicities. With a considerable unmet need for effective and tolerable treatments, HT-001 could provide much-needed relief for cancer patients grappling with debilitating skin reactions."

Mechanistically, HT-001 operates by obstructing the pro-inflammatory Substance P (SP)-NK1R pathway, which is pivotal in neurogenic inflammation. Previous research has demonstrated that HT-001 alleviates inflammation and mitigates hair loss often associated with EGFR inhibitor therapy. These recent clinical revelations bolster the drug's potential role within the realm of dermatologic oncology treatment options.

Currently, Hoth Therapeutics is advancing toward a Phase 2A clinical trial aimed at further assessing the efficacy and safety of HT-001 in a broader demographic. This trial will investigate how well HT-001 performs against various severities of EGFRi PPEs and extend its evaluation to other skin manifestations resulting from EGFR inhibitors.

For continued updates regarding HT-001 and its ongoing clinical evaluations, interested parties can visit Hoth Therapeutics' official website.
Hoth is committed to spearheading the development of innovative medical therapies designed to transform patients' lives, addressing key unmet medical needs through extensive research and collaboration.

Key Takeaways from the Announcement:

• - Efficacy: HT-001 displayed a rapid resolution of EGFR inhibitor-associated skin lesions in clinical observations.
• - Research Approach: Hoth is deeply engaged in ensuring that its product development aligns with patient-centric approaches and actively collaborates with experts in the field.
• - Future Directions: The subsequent clinical trial for HT-001 signifies Hoth's commitment to advancing cancer care through novel therapeutic solutions.

In summary, Hoth Therapeutics is poised to revolutionize the treatment landscape for patients experiencing debilitating skin reactions due to EGFR inhibitors, as demonstrated by the promising results of HT-001. The unfolding data at AAD 2025 promises further encouragement for both patients and practitioners seeking effective treatment avenues.